Ark Clinical Research Announces Advancing Accessibility for Obesity Through Innovative Research Trials on GLP-1 drugs
Ark Clinical Research (“Ark”) is advancing accessible solutions for obesity and obesity-related diseases through clinical research and a free health clinic, which administers health assessments and manages patient care.
- Ark Clinical Research (“Ark”) is advancing accessible solutions for obesity and obesity-related diseases through clinical research and a free health clinic, which administers health assessments and manages patient care.
- While the clinical research organization conducts Phase I-IV clinical trials in various therapeutic areas, the company is particularly focused on weight loss studies and accessibility of these drugs for those in need, particularly for low-income and minority patients.
- While these studies are placebo controlled, they can provide another avenue for GLP-1 drugs or other obesity drugs.
- If you are interested in learning more about Ark Clinical Research, please contact Samira Moran, CEO by phone at 310-710-2985 or by email at [email protected] .